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Introduction {#cam41401-sec-0001}
============

Colon cancer is among the leading causes of cancer‐related deaths all over the world [1](#cam41401-bib-0001){ref-type="ref"}, [2](#cam41401-bib-0002){ref-type="ref"}. Mountain of studies has showed that right‐sided colon cancer (RSCC) and left‐sided colon cancer (LSCC) should be considered as two distinct disease entities [3](#cam41401-bib-0003){ref-type="ref"}, [4](#cam41401-bib-0004){ref-type="ref"}, [5](#cam41401-bib-0005){ref-type="ref"}, [6](#cam41401-bib-0006){ref-type="ref"}. Differences in embryologic development, clinical presentation, patient demographics, and tumor biology between RSCC and LSCC have been clearly reported in the literatures [3](#cam41401-bib-0003){ref-type="ref"}, [5](#cam41401-bib-0005){ref-type="ref"}, [6](#cam41401-bib-0006){ref-type="ref"}, [7](#cam41401-bib-0007){ref-type="ref"}, [8](#cam41401-bib-0008){ref-type="ref"}, [9](#cam41401-bib-0009){ref-type="ref"}. It is well known that RSCC arises from the embryonic midgut and is perfused by the superior mesenteric artery, while LSCC originates from the hindgut and is served by the inferior mesenteric artery [6](#cam41401-bib-0006){ref-type="ref"}. Moreover, the capillary network surrounding the LSCC is multilayered, whereas that of the LSCC is single‐layered, possibly relating to the greater water absorption and electrolyte transport capacity of the former [10](#cam41401-bib-0010){ref-type="ref"}. The difference in anatomic structure may partly explain the different clinical presentation between RSCC and LSCC, such as more advanced T stage with severe symptoms (passage trouble or abdominal mass) in RSCC patients [7](#cam41401-bib-0007){ref-type="ref"}, [11](#cam41401-bib-0011){ref-type="ref"}.

Whether the biologic and clinical differences between RSCC and LSCC have translated into clinically meaningful prognostic difference is still controversial. Although accumulating evidences suggest that RSCC patients have a worse prognosis than LSCC patients [4](#cam41401-bib-0004){ref-type="ref"}, [5](#cam41401-bib-0005){ref-type="ref"}, [12](#cam41401-bib-0012){ref-type="ref"}, [13](#cam41401-bib-0013){ref-type="ref"}, [14](#cam41401-bib-0014){ref-type="ref"}, [15](#cam41401-bib-0015){ref-type="ref"}, [16](#cam41401-bib-0016){ref-type="ref"}, Weiss JM et al. [15](#cam41401-bib-0015){ref-type="ref"} used the Medicare beneficiaries of colon adenocarcinoma to compare survival between RSCC and LSCC patients by stage and found that there was no overall difference in 5‐year mortality between RSCC and LSCC patients. Their further analysis showed that stage II RSCC had lower mortality, while stage III RSCC had higher mortality than LSCC [15](#cam41401-bib-0015){ref-type="ref"}. Except for stage, are there other factors affecting the survival comparison between RSCC and LSCC patients? In this study, we used data from Surveillance, Epidemiology, and End Results (SEER) cancer registry program of individuals diagnosed with colon adenocarcinoma from 2004 to 2013 to compare the survival and clinicopathologic features between RSCC and LSCC patients in different situations.

Methods {#cam41401-sec-0002}
=======

Statistics {#cam41401-sec-0003}
----------

The patients' demographic and tumor characteristics were summarized with descriptive statistics. Comparisons of categorical variables between right and left colon cancer patients were performed using the chi‐squared test, and continuous variables were compared using Student\'s *t* test. The primary endpoint of this study was 5‐year cause‐specific survival (CSS), which was calculated from the date of diagnosis to the date of cancer‐specific death. Deaths attributed to colon cancer were treated as events, and deaths from other causes were treated as censored observations. Survival function estimation and comparison between RSCC and LSCC were performed using Kaplan--Meier estimates and the log‐rank test. The independence of the prognostic effect of location was evaluated by adjusting for other known factors including age at diagnosis and tumor stage. The multivariate Cox proportional hazard model was used to evaluate the hazard ratio (HR) and the 95% confidence interval (CI) for all the prognostic factors. All of statistical analyses were performed using the Intercooled Stata 13.0 (Stata Corporation, College Station, TX). Statistical significance was set at two‐sided *P *\<* *0.05.

Database {#cam41401-sec-0004}
--------

The SEER database is the largest publicly available cancer dataset. It is a population‐based cancer registry across several disparate geographic regions. The SEER research data include cancer incidence and prevalence as well as demographic information tabulated by age, sex, race/ethnicity, year of diagnosis, and geographic region. The dataset we used for this analysis was Surveillance, Epidemiology, and End Results (SEER) Program (<http://www.seer.cancer.gov>) Research Data (1973--2013).

Outcome variables {#cam41401-sec-0005}
-----------------

The anatomic subsites of the left colon and right colon were categorized according to the International Classification of Diseases for Oncology, third edition (ICD‐0‐3) topography codes. RSCC was identified with the following SEER cancer site codes: cecum (ICD‐0‐3 code C18.0), ascending colon (Code C18.2), hepatic flexure (Code C18.3), and transverse colon (Code C18.4). LSCC was identified with codes: splenic flexure (Code C18.5), descending colon (code C18.6), and sigmoid colon (code C18.7). Rectosigmoid (code C19.9) was excluded from the analysis.

For the Race/Ethnicity, we reclassified the patients into four groups: "Caucasian" (Race/Ethnicity code, 1), "African American" (Race/Ethnicity code, 2), "Asian" (Race/Ethnicity code, 4--6, 8--17 and 96), and "Others" (The rest code).

In this article, only adenocarcinoma patients were enrolled (SEER histology codes: signet ring cell, 8490; mucinous adenocarcinoma, 8480 and 8481; other adenocarcinoma: 8140--8147, 8210--8211, 8220--8221, 8260--8263, and 8570--8576).

Patient population {#cam41401-sec-0006}
------------------

The study population was based on the SEER cancer registry. Since the American Joint Committee on Cancer (AJCC) 7th Tumor‐Node‐Metastasis (TNM) staging system was released in 2010 and if we used this staging system, there would be no 5‐year survival due to insufficient follow‐up, so we picked up the AJCC 6th TNM staging systems. Meanwhile, since the AJCC 6th TNM staging system was released in 2004, we selected patients from 2004 to 2013.

All patients had active follow‐up and the survival month was over 1 month. Patients were excluded if they had more than one primary cancer, but colon cancer was not the first one or had unknown cause of death. AJCC 6th TNM staging systems were used for the staging. We excluded patients whose TNM stage was unknown.

Results {#cam41401-sec-0007}
=======

Patient baseline characteristics {#cam41401-sec-0008}
--------------------------------

The study identified 163,232 colon adenocarcinoma patients including 80,599 (49.38%) men and 82.633 (50.62%) women. Of these patients, 95,847 (58.72%) were RSCC and 67,385 (41.28%) were LSCC. The mean age of the whole population was 67.28 ± 13.61 (Mean ± SD) with a median age of 68 years old.

Clinicopathologic features of patients with RSCC and LSCC {#cam41401-sec-0009}
---------------------------------------------------------

Table [1](#cam41401-tbl-0001){ref-type="table-wrap"} showed the basic features between these two groups of patients. The proportion of men was significantly higher in LSCC than in RSCC patients, *P *\<* *0.001. The median age of LSCC patients was significantly younger than RSCC patients, 64 and 71 years old, respectively, *P *\<* *0.001. More LSCC patients were married. For the TNM stage, LSCC patients had higher percentage of stage I and IV diseases. Poorly differentiated and undifferentiated adenocarcinoma or mucinous adenocarcinoma/signet ring cell carcinoma was less common in LSCC than in RSCC patients. LSCC was more likely to be detected at a smaller tumor size than RSCC patients (median tumor size: 40 mm vs. 45 mm), *P *\<* *0.001. RSCC patients received more surgery and less radiation than LSCC patients. For those receiving operation, RSCC had more lymph nodes resected and fewer positive lymph nodes.

###### 

Comparison of clinicopathological features between right‐sided and left‐sided colon cancer

                                    Right‐sided colon (%)   Left‐sided colon (%)   *P* values
  --------------------------------- ----------------------- ---------------------- ------------
  Gender                                                                           
  Male                              44,112 (46.02)          36,487 (54.15)         
  Female                            51,735 (53.98)          30,898 (45.85)         \<0.001
  Age (Mean ± SD)                   69.49 ± 13.27           64.15 ± 13.48          \<0.001
  Ethnicity                                                                        
  Caucasian (%)                     76,668 (79.99)          51,372 (76.24)         
  African American                  12,475 (13.02)          8169 (12.12)           
  Asian                             5449 (5.69)             6457 (9.58)            
  Others                            1255 (1.31)             1387 (2.06)            \<0.001
  Married status                                                                   
  Married                           50,435 (52.62)          37,786 (56.07)         
  Unmarried                         41,308 (43.10)          26,265 (38.98)         
  Unknown                           4104 (4.28)             3334 (4.95)            \<0.001
  AJCC 6th TNM stage                                                               
  I                                 21,561 (22.5)           18,638 (27.66)         
  II                                30,186 (31.49)          17,058 (25.31)         
  III                               27,015 (28.19)          18,602 (27.61)         
  IV                                17,085 (17.83)          13,087 (19.42)         \<0.001
  AJCC 6th T stage                                                                 
  T0                                13 (0.01)               10 (0.01)              
  T1                                12,315 (12.85)          14,816 (21.99)         
  T2                                13,675 (14.27)          7859 (11.66)           
  T3                                51,953 (54.20)          32,630 (48.42)         
  T4                                15,033 (15.68)          9736 (14.45)           
  TX                                2858 (2.98)             2334 (3.46)            \<0.001
  AJCC 6th N stage                                                                 
  N0                                55,463 (57.87)          39,355 (58.4)          
  N1                                22,642 (23.62)          16,687 (24.76)         
  N2                                15,984 (16.68)          9868 (14.64)           
  NX                                1758 (1.83)             1475 (2.19)            \<0.001
  Histology                                                                        
  Other adenocarcinoma              82,848 (86.44)          62,884 (93.32)         
  Mucinous adenocarcinoma           11,625 (12.13)          4055 (6.02)            
  Signet ring cell                  1374 (1.43)             446 (0.66)             \<0.001
  Grade                                                                            
  Well differentiated               7688 (8.02)             6344 (9.41)            
  Moderately differentiated         61,096 (63.74)          46,809 (69.47)         
  Poorly differentiated             19,639 (20.49)          8385 (12.44)           
  Undifferentiated                  2257 (2.35)             829 (1.23)             
  Unknown                           5167 (5.39)             5018 (7.45)            \<0.001
  Lymph node resected (Mean ± SD)   17.97 ± 13.48           14.51 ± 13.69          \<0.001
  Positive lymph node (Mean ± SD)   10.01 ± 26.94           15.94 ± 34.22          \<0.001
  Tumor size (Mean ± SD, mm)        49.79 ± 36.82           43.80 ± 30.33          \<0.001
  Surgery                                                                          
  Yes                               90,084 (93.99)          62,675 (93.01)         
  No                                5708 (5.96)             4662 (6.92)            
  Unknown                           55 (0.06)               48 (0.07)              \<0.001
  Radiation                                                                        
  Yes                               1261 (1.32)             2037 (3.02)            
  No                                93,920 (97.99)          64,788 (96.15)         
  Unknown                           666 (0.69)              560 (0.83)             \<0.001

AJCC, American Joint Committee on Cancer; SD, standard deviation; TNM, Tumor‐Node‐Metastasis.
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Survival analysis {#cam41401-sec-0010}
-----------------

The 5‐year CSS for the whole population was 69.3% (95% CI: 69.0--69.5%). There were 25,489 deaths (26.59%) in RSCC patients and 16,457 (24.42%) in LSCC patients. The 5‐year CSS was significantly longer in LSCC patients than in RSCC patients, 70.9% versus 68.1%, *P *\<* *0.001.

The median age of the whole population was 68 years old. We therefore divided the patients into two groups according to the age: \<69 years old (younger patients) and \>68 years old (older patients). The younger patients had a significantly better 5‐year CSS than the older patients (71.2% vs. 67.2%, *P *\<* *0.001; Table [2](#cam41401-tbl-0002){ref-type="table-wrap"}).

###### 

Survival analysis in the whole population

                              5‐year CSS   95% CI        *P* value
  --------------------------- ------------ ------------- -----------
  Gender                                                 
  Male                        69.0%        68.6--69.4%   
  Female                      69.5%        69.1--69.9%   0.5552
  Age                                                    
  \<69                        71.2%        70.8--71.6%   
  \>68                        67.2%        66.8--67.6%   \<0.001
  Ethnicity                                              
  Caucasian                   70.1%        69.8--70.4%   
  African American            62.0%        61.2--62.8%   
  Asian                       71.8%        70.8--72.7%   
  Others                      74.2%        71.7--76.5%   \<0.001
  Married status                                         
  Married                     72.1%        71.7--72.4%   
  Unmarried                   65.3%        64.8--65.7%   
  Unknown                     73.9%        72.7--75.1%   \<0.001
  Location                                               
  Left‐sided colon            70.9%        70.5--71.3%   
  Right‐sided colon           68.1%        67.7--68.4%   \<0.001
  AJCC 6th TNM stage                                     
  I                           93.6%        93.3--93.9%   
  II                          84.8%        84.4--85.2%   
  III                         68.3%        67.8--68.8%   
  IV                          13.1%        12.6--13.6%   \<0.001
  Histology                                              
  Other adenocarcinoma        70.1%        69.8--70.4%   
  Mucinous adenocarcinoma     65.3%        64.4--66.1%   
  Signet ring cell            37.1%        34.5--39.7%   \<0.001
  Grade                                                  
  Well differentiated         83.0%        82.2--83.7%   
  Moderately differentiated   72.8%        72.4--73.1%   
  Poorly differentiated       55.9%        55.2--56.5%   
  Undifferentiated            54.5%        52.3--56.8%   
  Unknown                     54.2%        53.1--55.3%   \<0.001
  Lymph node resected                                    
  \<12                        61.5%        61.1--62.0%   
  ≥12                         73.2%        72.8--73.5%   \<0.001
  Size                                                   
  ≤43 mm                      77.1%        76.7--77.4%   
  \>43 mm                     63.4%        63.0--63.7%   \<0.001
  Surgery                                                
  Yes                         73.0%        72.7--73.2%   
  No                          9.3%         8.6--10.1%    
  Unknown                     26.8%        19.8--34.3%   \<0.001
  Radiation                                              
  Yes                         46.0%        44.0--48.0%   
  No                          69.8%        69.5--70.1%   
  Unknown                     62.5%        59.1--65.8%   \<0.001

AJCC, American Joint Committee on Cancer; CI, Confidence interval; CSS, Cause‐specific survival; TNM, Tumor‐Node‐Metastasis.
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No doubt, the TNM stage was significantly correlated with survival. The 5‐year CSS was 93.6%, 84.8%, 68.3%, and 13.1% for patients from stage I to stage IV, respectively, *P *\<* *0.001. For the histology subtypes, signet ring cells had worse 5‐year CSS than the mucinous adenocarcinoma and other adenocarcinoma. When we analyzed the 5‐year CSS in patients with different grades, we found that the survival became poorer as the tumor grades progressed from well to undifferentiated, 83.0% for well differentiated, 72.8% for moderately differentiated, 55.9% for poorly differentiated, and 54.2% for undifferentiated tumors, *P *\<* *0.001.

Multivariate analysis {#cam41401-sec-0011}
---------------------

Variables showing a trend for association with survival (*P *\<* *0.05) were selected in the Cox proportional hazards model. Age, married status, ethnicity, location, TNM stage, histologic subtypes, grade, tumor size, as well as surgery were all independent prognostic factors in the multivariable analysis. Compared with RSCC patients, the HR for LSCC patients was 0.87, 95% CI: 0.85--0.89, *P *\<* *0.001 (Table [3](#cam41401-tbl-0003){ref-type="table-wrap"}).

###### 

Multivariate analysis

                              Hazard ratio   95% CI         *P* value
  --------------------------- -------------- -------------- -----------
  Age                                                       
  \<69                        Reference                     
  \>68                        1.71           1.68--1.75     \<0.001
  Ethnicity                                                 
  Caucasian                   Reference                     
  African American            1.17           1.14--1.20     \<0.001
  Asian                       0.87           0.84--0.91     \<0.001
  Others                      1.06           0.98--1.15     0.172
  Married status                                            
  Married                     Reference                     
  Unmarried                   1.23           1.21--1.26     \<0.001
  Unknown                     1.04           0.98--1.09     0.167
  Location                                                  
  Right‐sided colon           Reference                     
  Left‐sided colon            0.87           0.85--0.89     \<0.001
  AJCC 6th TNM stage                                        
  I                           Reference                     
  II                          2.13           2.03--2.24     \<0.001
  III                         5.03           4.81--5.27     \<0.001
  IV                          23.03          22.01--24.11   \<0.001
  Histology                                                 
  Other adenocarcinoma        Reference                     
  Mucinous adenocarcinoma     1.09           1.05--1.12     \<0.001
  Signet ring cell            1.41           1.32--1.51     \<0.001
  Grade                                                     
  Well differentiated         Reference                     
  Moderately differentiated   1.15           1.10--1.21     \<0.001
  Poorly differentiated       1.61           1.54--1.69     \<0.001
  Undifferentiated            1.76           1.64--1.90     \<0.001
  Unknown                     1.27           1.20--1.34     \<0.001
  Size                                                      
  ≤43 mm                      Reference                     
  \>43 mm                     1.18           1.15--1.20     0.005
  Surgery                                                   
  No                          Reference                     
  Yes                         0.56           0.42--0.77     \<0.001
  Unknown                     0.85           0.65--1.12     0.252
  Radiation                                                 
  Yes                         Reference                     
  No                          0.98           0.48--2.00     0.95
  Unknown                     1.22           0.60--2.47     0.587

AJCC, American Joint Committee on Cancer; CI, Confidence interval; TNM, Tumor‐Node‐Metastasis.
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Survival difference between RSCC and LSCC in different situations {#cam41401-sec-0012}
-----------------------------------------------------------------

We further compared the survival difference between RSCC and LSCC in different situations (Table [4](#cam41401-tbl-0004){ref-type="table-wrap"}). We found that LSCC patients had better prognosis than RSCC in both men and women, younger patients, all ethnicity subgroups, different married status, well and moderately differentiated adenocarcinoma patients and also in all the tumor sizes, and in patients receiving different therapies.

###### 

Survival difference between RSCC and LSCC in different situations

                              Right‐sided colon     Left‐sided colon      *P* value
  --------------------------- --------------------- --------------------- -----------
  Gender                                                                  
  Male                        67.8% (67.3--68.3%)   70.7% (70.2--71.3%)   \<0.001
  Female                      68.5% (68.1--67.0%)   71.4% (70.8--72.0%)   \<0.001
  Age                                                                     
  \<69                        69.1% (68.6--69.6%)   73.5% (73.0--74.0%)   \<0.001
  \>68                        67.5% (67.1--68.0%)   67.1% (66.4--67.7%)   0.5084
  Ethnicity                                                               
  Caucasian                   69.1% (68.9--69.7%)   71.9% (71.4--72.3%)   \<0.001
  African American            61.6% (60.5--62.6%)   63.0% (61.8--64.3%)   0.0041
  Asian                       70.8% (69.4--72.2%)   74.2% (72.9--75.5%)   \<0.001
  Others                      68.1% (64.8--71.2%)   73.1% (70.2--75.9%)   0.0134
  Married status                                                          
  Married                     70.6% (70.2--71.1%)   74.0% (73.5--74.5%)   \<0.001
  Unmarried                   64.9% (64.3--65.4%)   65.9% (65.2--66.6%)   \<0.001
  Unknown                     71.2% (69.4--72.8%)   77.3% (75.5--79.0%)   \<0.001
  AJCC 6th TNM stage                                                      
  I                           92.8% (92.4--93.2%)   94.6% (94.2--95.0%)   \<0.001
  II                          85.5% (85.0--86.0%)   83.7% (83.0--84.3%)   \<0.001
  III                         64.9% (64.2--65.6%)   73.4% (72.6--74.2%)   \<0.001
  IV                          11.2% (10.6--11.9%)   16.2% (15.4--17.0%)   \<0.001
  AJCC 6th T stage                                                        
  T1                          84.3% (83.6--85.0%)   89.9% (89.4--90.5%)   \<0.001
  T2                          90.7% (90.1--91.2%)   91.0% (90.2--91.7%)   0.4867
  T3                          70.5% (70.0--71.0%)   70.5% (69.9--71.0%)   0.053
  T4                          37.1% (36.1--38.1%)   40.6% (39.3--41.8%)   \<0.001
  AJCC 6th N stage                                                        
  N0                          83.8% (83.5--84.2%)   83.2% (82.7--83.6%)   0.1428
  N1                          59.5% (58.7--60.2%)   64.4 (63.5--65.2%)    \<0.001
  N2                          33.8% (32.9--34.6%)   44.0% (42.8--45.2%)   \<0.001
  Histology                                                               
  Other adenocarcinoma        68.8% (68.4--69.2%)   72.1% (71.6--72.5%)   \<0.001
  Mucinous adenocarcinoma     67.3% (66.3--68.3%)   60.0% (58.2--61.7%)   \<0.001
  Signet ring cell            39.4% (36.3--42.4%)   31.0% (26.0--36.1%)   0.0034
  Grade                                                                   
  Well differentiated         82.1% (81.0--83.0%)   84.2% (83.2--85.3%)   0.0011
  Moderately differentiated   72.5% (72.1--72.9%)   73.4% (72.9--73.8%)   \<0.001
  Poorly differentiated       56.2% (55.4--57.0%)   55.7% (54.5--57.0%)   0.0813
  Undifferentiated            54.9% (52.2--57.5%)   54.0% (49.6--58.2%)   0.5098
  Unknown                     47.7% (46.2--49.3%)   61.2% (59.6--62.7%)   \<0.001
  Lymph nodes resected                                                    
  \<12                        55.6% (54.9--56.3%)   67.1% (66.4--67.7%)   \<0.001
  ≥12                         72.9% (72.5--73.3%)   73.9% (73.4--74.5%)   \<0.001
  Tumor size                                                              
  ≤43 mm                      76.6% (76.1--77.0%)   77.7% (77.1--78.2%)   \<0.001
  \>43 mm                     62.0% (61.6--62.5%)   65.4% (64.8--66.0%)   \<0.001
  Surgery                                                                 
  Yes                         71.7% (71.4--72.1%)   75.0% (74.6--75.4%)   \<0.001
  No                          7.3% (6.4--8.2%)      12.8% (11.5--14.1%)   \<0.001
  Unknown                     31.3% (16.5--47.3%)   35.7% (20.6--51.1%)   0.9440
  Radiation                                                               
  Yes                         33.6% (30.5--36.6%)   53.8% (51.3--56.4%)   \<0.001
  No                          68.7% (68.4--69.1%)   71.7% (71.2--72.1%)   \<0.001
  Unknown                     59.9% (55.2--64.3%)   65.9% (60.9--70.4%)   0.0287

AJCC, American Joint Committee on Cancer; LSCC, Left‐sided colon cancer; RSCC, Right‐sided colon cancer; TNM, Tumor‐Node‐Metastasis.
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There was no significant difference between RSCC and LSCC in older patients or in those with poorly differentiated or undifferentiated adenocarcinoma. Meanwhile, no survival difference between RSCC and LSCC in T2, T3 or N0 disease was found.

For patients with different TNM stages, LSCC had a better prognosis than RSCC except for stage II disease (Fig. [1](#cam41401-fig-0001){ref-type="fig"}). Surprisingly, the survival trend reversed in stage II disease, 83.7% and 85.5% for LSCC and RSCC patients, respectively, *P *\<* *0.001. As we know that when the resected number of lymph nodes was \<12, it may lead to inappropriate staging, especially for stage II disease. To better understand the survival difference in stage II disease, we analyzed the survival difference between RSCC and LSCC when resected lymph nodes were less 12 and over 11, respectively (Fig. [2](#cam41401-fig-0002){ref-type="fig"}). We found that there was no significant survival difference between these two groups when the resected number of lymph nodes was less 12, *P *=* *0.7829 (Fig. [2](#cam41401-fig-0002){ref-type="fig"}A). When the resected number of lymph nodes was over 11, stage II RSCC patients had significantly better prognosis than LSCC patients, *P *=* *0.0228 (Fig. [2](#cam41401-fig-0002){ref-type="fig"}B).

![Kaplan--Meier survival estimates for patients with right‐sided and left‐sided colon cancer in (A) stage I disease; (B) stage II disease; (C) stage III disease; and (D) stage IV disease.](CAM4-7-1141-g001){#cam41401-fig-0001}

![Kaplan--Meier survival estimates for stage II patients with right‐sided and left‐sided colon cancer when the number of resected lymph nodes was \<12 (A); over 11 (B).](CAM4-7-1141-g002){#cam41401-fig-0002}

Moreover, LSCC patients also had a poorer survival than RSCC when the histology subtypes were mucinous adenocarcinoma or signet ring cell carcinoma (Fig. [3](#cam41401-fig-0003){ref-type="fig"}).

![Kaplan--Meier survival estimates for patients with right‐sided and left‐sided colon cancer in (A) Other adenocarcinoma; (B) Mucinous adenocarcinoma; and (C) Signet ring cell carcinoma.](CAM4-7-1141-g003){#cam41401-fig-0003}

Clinicopathologic features of stage II patients between RSCC and LSCC patients {#cam41401-sec-0013}
------------------------------------------------------------------------------

To understand why LSCC patients had poorer survival than RSCC in stage II diseases, we compared the clinicopathologic features of stage II patients between RSCC and LSCC (Appendix [S1](#cam41401-sup-0001){ref-type="supplementary-material"}). Overall, the clinicopathologic features between RSCC and LSCC were similar in stage II disease and in the whole population. Except that LSCC patients had more T4 diseases than RSCC in stage II while in the whole population, LSCC had less T4 diseases.

Clinicopathologic features of mucinous adenocarcinoma/signet ring cell carcinoma patients between RSCC and LSCC patients {#cam41401-sec-0014}
------------------------------------------------------------------------------------------------------------------------

Similarly, we compared the clinicopathologic features of mucinous adenocarcinoma/signet ring cell carcinoma patients between RSCC and LSCC patients (Appendix [S2](#cam41401-sup-0001){ref-type="supplementary-material"}). Compared with the whole population, more RSCC patients had stage I disease in mucinous adenocarcinoma/signet ring cell carcinoma patients.

Discussion {#cam41401-sec-0015}
==========

A number of studies have been carried out in different regions of the world to describe the differences between RSCC and LSCC. Regarding the difference in biologic behavior and clinical presentation, RSCC and LSCC were suggested to be considered as two disease entities [5](#cam41401-bib-0005){ref-type="ref"}, [9](#cam41401-bib-0009){ref-type="ref"}, [15](#cam41401-bib-0015){ref-type="ref"}, [17](#cam41401-bib-0017){ref-type="ref"}. In this study, we found that the relationship between clinicopathologic features and tumor location in colon cancer was not straightforward. Specifically, RSCC patients not only had some adverse features, such as older, more unmarried, more advanced T and N stage, larger tumor sizes, and more poorly differentiated tumor which were similar to the previous reports [6](#cam41401-bib-0006){ref-type="ref"}, [11](#cam41401-bib-0011){ref-type="ref"}, [13](#cam41401-bib-0013){ref-type="ref"}, [15](#cam41401-bib-0015){ref-type="ref"}, [18](#cam41401-bib-0018){ref-type="ref"}, [19](#cam41401-bib-0019){ref-type="ref"}, but also had some good features, including less metastasis diseases and fewer numbers of positive lymph nodes. Most previous comparisons of clinicopathological features between RSCC and LSCC only included stage I‐III diseases and they concluded that RSCC had more advanced stages [5](#cam41401-bib-0005){ref-type="ref"}, [15](#cam41401-bib-0015){ref-type="ref"}, [20](#cam41401-bib-0020){ref-type="ref"}, [21](#cam41401-bib-0021){ref-type="ref"}, [22](#cam41401-bib-0022){ref-type="ref"}. Here, we pointed out that actually RSCC patients had less metastasis diseases than LSCC. The complicated relationship between clinicopathologic features and tumor location in colon cancer might partly explain the controversial results of survival comparison between RSCC and LSCC patients [4](#cam41401-bib-0004){ref-type="ref"}, [5](#cam41401-bib-0005){ref-type="ref"}, [12](#cam41401-bib-0012){ref-type="ref"}, [13](#cam41401-bib-0013){ref-type="ref"}, [14](#cam41401-bib-0014){ref-type="ref"}, [15](#cam41401-bib-0015){ref-type="ref"}, [16](#cam41401-bib-0016){ref-type="ref"}. Some found that RSCC had better survival than LSCC [11](#cam41401-bib-0011){ref-type="ref"}, [18](#cam41401-bib-0018){ref-type="ref"}, [19](#cam41401-bib-0019){ref-type="ref"}, [20](#cam41401-bib-0020){ref-type="ref"}, [23](#cam41401-bib-0023){ref-type="ref"}. Other studies considered that location of colon had no relationship with survival [15](#cam41401-bib-0015){ref-type="ref"}, [24](#cam41401-bib-0024){ref-type="ref"}. Thinking about the controversial results in the literatures, we hypothesized that the comparison of survival between RSCC and LSCC might vary in different situations.

Here, we firstly reported that RSCC had better prognosis than LSCC in mucinous adenocarcinoma/signet ring cell carcinoma patients. Except for this, RSCC also had better prognosis than LSCC in stage II diseases when the number of resected lymph nodes was over 11, consistent with previous reports [15](#cam41401-bib-0015){ref-type="ref"}, [19](#cam41401-bib-0019){ref-type="ref"}, [21](#cam41401-bib-0021){ref-type="ref"}. To further understand the above findings, we compared the clinicopathologic features between RSCC and LSCC in stage II patients and mucinous adenocarcinoma/signet ring cell carcinoma patients. We found that the clinicopathologic features were similar in the subgroups and in the whole population. It seemed that the better survival of RSCC patients in the above two situations was more likely related to tumor biology. Previous study showed that survival in stage II/III colorectal cancer was independently predicted by microsatellite instability (MSI), but not by specific driver mutations [25](#cam41401-bib-0025){ref-type="ref"}. MSI is predominantly seen in RSCC (about 25%) [3](#cam41401-bib-0003){ref-type="ref"}, while \<5% in LSCC [6](#cam41401-bib-0006){ref-type="ref"}. Mucinous adenocarcinoma was more common in RSCC and was reported to have more MSI than nonmucinous adenocarcinoma [26](#cam41401-bib-0026){ref-type="ref"}. High MSI is related to a better overall survival [27](#cam41401-bib-0027){ref-type="ref"}, [28](#cam41401-bib-0028){ref-type="ref"}, [29](#cam41401-bib-0029){ref-type="ref"} despite the fact that the effect of adjuvant chemotherapy, especially 5‐fluorouracil, is reduced in patients with MSI [30](#cam41401-bib-0030){ref-type="ref"}. We hypothesized that MSI was the major contributor to the reverse mortality between RSCC and LSCC in stage II and mucinous adenocarcinoma/signet ring cell carcinoma patients. Further researches are needed to confirm our hypothesis.

In the multivariate analysis, we found that location was an independent prognostic factor in the whole population. LSCC had lower mortality rate than RSCC with a hazard ratio of 0.87. There were other studies using the SEER database or SEER‐Medicare database trying to explore the role of location on survival. In Weiss JM\'s study, they found no difference in 5‐year mortality between RSCC and LSCC patients [15](#cam41401-bib-0015){ref-type="ref"}. Their study was limited in the patients' age and stage. All the patients were 66 years and older and they only enrolled stage I to III patients. LSCC patients were younger and had more stage IV diseases [13](#cam41401-bib-0013){ref-type="ref"}. In our studies, we showed that LSCC had better prognosis than RSCC in younger patients and also stage IV patients. After excluding patients whose prognosis favoring LSCC, it was not hard to understand why no survival difference was found in Weiss JM\'s study. Meguid et al. [19](#cam41401-bib-0019){ref-type="ref"} analyzed patients who underwent surgical resection for invasive colon adenocarcinoma using the SEER database between 1988 and 2003, and found that RSCC had worse prognosis than LSCC patients, which was similar to our result. This study was also limited to patients' selection. Only patients who received surgical resection were considered. The patients' selection in our present study was more close to real world.

Potential limitations of our study should be taken into consideration. Unmeasured factors in SEER database, such as chemotherapy and tumor biology, including MSI status might play roles in patient outcome. Recent reports showed that RSCC and LSCC even had different response to the anti‐Epidermal growth factor receptor (EGFR) and anti‐Vascular endothelial growth factor (VEGF) monoclonal antibody [31](#cam41401-bib-0031){ref-type="ref"}. We could not fully evaluate the impact of chemotherapy and target therapy on survival of RSCC and LSCC patients.

In conclusion, the relationship between survival and tumor location in colon cancer was not straightforward. There is a need for further subdivisions when analyzing the survival difference between RSCC and LSCC. We found that RSCC patients had better prognosis than LSCC in stage II disease or mucinous adenocarcinoma/signet ring cell carcinoma patients.
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